| Literature DB >> 34917928 |
Jiaqi Fang1,2, Jiahong Lu1,2, Ying Zhang1,2, Jinyu Wang1,2, Sainan Wang1,2, Hongliang Fan1,2, Jiarui Zhang1,2, Weichang Dai1,2, Junpeng Gao1, Hansong Yu1,2.
Abstract
In this study, a method for preparing low molecular weight peptides (HPH-VAP) from okara using high-pressure homogenization assisted double enzymes was proposed. In order to explore its advantages, the effects of various methods on protein extraction rate and on the structure, antioxidant and immune properties of peptides were compared. The results showed that the protein extraction rate of this method was increased by 69% and 51% compared with other methods, and the structure only led to changes in the hydrogen bonds between peptide chains. HPH-VAP was screened out through functional characteristics, its structure was identified by HPLC-MS/MS, and further immunological activity analysis was carried out. The results showed that it promoted cell phagocytic ability, NO level and release of cytokines IL-6, IFN- γ, TNF-α. Therefore, this method is an effective and applicable method for industrial preparation of okara peptides, and has a positive effect on the reuse of okara resources.Entities:
Keywords: Antioxidation; Double enzyme hydrolysis; High-pressure homogenization; Immunity; Okara peptides
Year: 2021 PMID: 34917928 PMCID: PMC8645904 DOI: 10.1016/j.fochx.2021.100175
Source DB: PubMed Journal: Food Chem X ISSN: 2590-1575
Fig. 1Okara peptide obtained by different processing methods. Method one: HPH-VAP was pretreated by high pressure homogenization, and then directly prepared by enzymatic hydrolysis with Viscozyme L and Alcalase 2.4 L; method two: VAP was directly prepared by enzymatic hydrolysis of Viscozyme L and Alcalase 2.4 L successively; method three: OP was alkali-dissolved acid precipitation method to prepare protein and then enzymatic hydrolysis.
Fig. 2Characterization of the structure of okara peptide. (A)-(C) SEM of okara peptides; (D) Particle size distribution and zeta-potential of okara peptides;(E) FT-IR of okara peptides; (F) Circular dichroism of okara peptides; (G) Fluorescence spectroscopy of okara peptides.
Fig. 3Comparison of antioxidant and immune activity of okara peptides. Different letters indicate significant differences, A-D (same treatment), a-d (same concentration) (P < 0.05), mean values labelled with (*) are significantly different from the blank control group (i.e., *P < 0.05; ** P < 0.01; ***P < 0.001).
The peptides were scored by Peptide Ranker for predicting the potential for immune activity.
| No. | Sequence | Score |
|---|---|---|
| 1 | FLL | 0.953949 |
| 2 | FYL | 0.950547 |
| 3 | YLF | 0.950152 |
| 4 | EFW | 0.947113 |
| 5 | LLF | 0.938925 |
| 6 | AYF | 0.915352 |
| 7 | SWL | 0.913341 |
| 8 | FIL | 0.898768 |
| 9 | WNL | 0.898033 |
| 10 | DLF | 0.893079 |
| 11 | YIF | 0.892272 |
| 12 | FHL | 0.88902 |
| 13 | ILF | 0.884427 |
| 14 | FLI | 0.882207 |
| 15 | FDL | 0.870302 |
| 16 | LIF | 0.865651 |
| 17 | FYI | 0.858249 |
| 18 | FLD | 0.820681 |
| 19 | FLK | 0.805333 |
| 20 | FGPF | 0.995241 |
| 21 | FLSF | 0.965539 |
| 22 | DDFF | 0.965214 |
| 23 | FISF | 0.949218 |
| 24 | GWLG | 0.948294 |
| 25 | GWIG | 0.921154 |
| 26 | SLGF | 0.915554 |
| 27 | GDLF | 0.90902 |
| 28 | SIGF | 0.886873 |
| 29 | FGSL | 0.861457 |
| 30 | EDFF | 0.857384 |
| 31 | GDIF | 0.855158 |
| 32 | EPGF | 0.842858 |
| 33 | FFGPG | 0.98344 |
| 34 | FPYPR | 0.960542 |
| 35 | SPSPF | 0.928005 |
| 36 | HFDAF | 0.903091 |
| 37 | DDGPF | 0.88928 |
| 38 | SVPPF | 0.885107 |
| 39 | WWDAK | 0.864797 |
| 40 | WGEDW | 0.85414 |
| 41 | KDWVF | 0.825197 |
| 42 | AFTPL | 0.812467 |
| 43 | FYADP | 0.802557 |
| 44 | KDFLPF | 0.943593 |
| 45 | EFFDRF | 0.937159 |
| 46 | SFWDGK | 0.905982 |
| 47 | DDFDRF | 0.898629 |
| 48 | TFPYPR | 0.869334 |
| 49 | KDFPPR | 0.851136 |
| 50 | GYDDGF | 0.833562 |
| 51 | SWGEDW | 0.818031 |
| 52 | DFFDGK | 0.817769 |
| 53 | FEPPRY | 0.811904 |
| 54 | DYHDLF | 0.811285 |
Fig. 4MS/MS spectra showing the fragments for ten peptides. (A). FLL; (B) FYL; (C) YLF; (D) FLSF; (E) FGPF; (F) DDFF; (G) FFGPG; (H) FPYPR; (I) GNWGPL; (J) FDDFDRF.
Fig. 5The immunomodulatory activity of HPH-VAP and its effects on the production of inflammatory cytokines RAW264.7 macrophages. (A) Determination of NO production. Cells were treated with DMEM (Control), LPS (Model, 1 μg/mL) and HPH-VAP for 24 h. (B, C and D) Determination of IL-6, IFN-γ and TNF-α contents in the medium supernatants. Cells were treated with DMEM (Control), LPS (Model, 1 μg/mL) and HPH-VAP for 24 h, mean values labelled with (*) are significantly different from the blank control group (i.e., *P < 0.05; ** P < 0.01; ***P < 0.001; ****P < 0.0001).